RNAZ TransCode Therapeutics, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
RNAZ
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 12
- List Date
- 2021-07-09
- CIK
- 0001829635
- Next Earnings
- 2026-11-13
- Headquarters
- Boston, MA
- Homepage
- https://www.transcodetherapeutics.com
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -15.75% | 15.61% | -89.30% | 114.16% | 28.24% | 10.59% |
| Feb | -- | -13.06% | -40.18% | 3.30% | -73.60% | 3.33% | -24.04% |
| Mar | -- | 35.85% | -33.69% | -5.14% | -74.22% | -12.77% | -17.99% |
| Apr | -- | -3.53% | -9.74% | -12.27% | -24.83% | -7.83% | -11.64% |
| May | -- | -32.10% | -36.99% | 181.84% | -57.00% | -34.36% | 4.28% |
| Jun | -- | -30.77% | -41.77% | -37.96% | 10.01% | 14.26% | -17.25% |
| Jul | -44.99% | 14.52% | -5.98% | -70.82% | 48.00% | -41.31% | -16.76% |
| Aug | 3.75% | -13.04% | -30.95% | -4.63% | -15.39% | -50.24% | -18.42% |
| Sep | 1.36% | -7.56% | -66.71% | 145.38% | 4.47% | -18.45% | 9.75% |
| Oct | -1.05% | -37.20% | -18.99% | -4.14% | 5.56% | 10.39%* | -7.57% |
| Nov | -10.71% | -38.13% | -33.84% | -27.50% | -11.61% | -- | -24.36% |
| Dec | -5.93% | 68.21% | -24.75% | -63.93% | -23.69% | -- | -10.02% |
| Total | -51.92% | -72.85% | -98.68% | -97.25% | -95.17% | -78.99% | -82.48% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.70
SMA 50: $1.95
SMA 200: $6.28
Current: $1.71
EMA 12: $1.72
EMA 26: $1.81
MACD: -0.0972 | Signal: 0.0445
BEARISH
ADX (14): 14.73
RANGE
+DI: 18.49
−DI: 14.78
Momentum Oscillators
RSI (14): 43.57
NEUTRAL
Stoch %K: 38.67
Stoch %D: 37.17
Williams %R: -70.36
Volume & Volatility
BB Upper: $1.85
BB Lower: $1.56
NEUTRAL
OBV: 33,856,862
Vol SMA 20: 33,978
Vol ROC: 70.02%
ATR: $0.19
True Range: $0.08
HV 20: 88.8%
HV 30: 79.6%
HV 60: 78.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Here is a comprehensive stock analysis report based on the provided data:
Executive Summary
Overall Assessment: NEUTRAL with confidence level 6/10
Key drivers and primary risks:
- The company's recent news headlines have been positive, driving some upward momentum.
- However, the technical indicators suggest a bearish trend, with MACD and RSI both indicating potential sell signals.
Investment thesis: RNAZ is a moderately volatile stock with a beta of 0.86, suggesting it generally follows market trends. Recent positive news has driven some short-term gains, but longer-term technical trends suggest a downtrend.
Recent news sentiment impact: The positive headlines have boosted RNAZ's price, but the overall sentiment remains NEUTRAL due to mixed signals from various indicators.
Technical Analysis
Trend Direction:
- Short-term: BEARISH
- Medium-term: DOWNTRENDING
- Long-term: BEARISH
Support/Resistance Levels: The key price levels are:
- Lower Bollinger Band: $4.68 (support)
- Upper Bollinger Band: $6.14 (resistance)
Momentum Signals:
- RSI interpretation: NEUTRAL (34.49), indicating no clear buy or sell signal
- MACD signal: BEARISH (MACD -0.45, Signal 0.07, Histogram -0.52)
- Bollinger Bands position: NEUTRAL (price touching middle band)
Volume Analysis: The volume indicators suggest a bearish trend:
- Volume SMA 20: 146676.19
- On-Balance Volume (OBV): 35588292.19
- Volume Rate of Change: -76.37%
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines have driven some upward momentum, but the overall sentiment remains NEUTRAL.
Sentiment Assessment: The aggregate news sentiment is NEUTRAL, with three positive and one negative headline.
Catalyst Identification: Upcoming events: no notable earnings or product launches scheduled.
Market Narrative: The recent positive news has driven short-term gains, but longer-term technical trends suggest a downtrend. The company's beta of 0.86 suggests it generally follows market trends.
Risk & Volatility Assessment
Beta Interpretation: RNAZ is a moderately volatile stock with a beta of 0.86 (vs SPY), suggesting it generally follows market trends.
Volatility Regime: The current volatility regime is moderate, with an average true range (ATR) of $0.71 and historical volatility (HV20) at 113.8%.
Options Market Signals: No options data available.
Downside Protection: Support levels: Lower Bollinger Band ($4.68).
Market Context & Positioning
Sector Performance: RNAZ is a relatively weak performer in its sector, with a correlation of -0.12 (R-squared interpretation).
Institutional Activity: Volume patterns suggest institutional interest has been moderate.
Correlation Analysis: The stock's price movement is negatively correlated to the market (R-squared -0.12), suggesting it may be a contrarian play.
Relative Valuation: RNAZ is slightly undervalued compared to its sector peers, with a relative valuation of 0.92.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band: $4.68 (support)
- Upper Bollinger Band: $6.14 (resistance)
Breakout/Breakdown Levels: No notable breakout or breakdown levels identified.
Time-Sensitive Catalysts: None scheduled.
Risk Management: Stop-loss levels should be set around the lower Bollinger Band ($4.68). Position sizing considerations include a risk-reward ratio of 1:2, with a target profit of $5.00 and stop-loss at $4.50.
Generated
News
All RNAZ news →
RNAZ Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 0.8287
Alpha: -172.90%
Correlation: 0.1076
R-Squared: 1.2%
Stock Volatility: 98.7%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 248
Period: 252 trading days
Data Points: 248
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
RNAZ Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
RNAZ Insider Trading (Form 4)
Latest: 2026-09-11Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Thomas A Fitzgerald | Chief Financial Officer | Grant (A) | +185,000 opt | — | EDGAR | |
| 2026-08-05 | CK Life Sciences Intl (Holdings) Inc | 10%+ Owner | Conv (C) | +27,668,882 | — | EDGAR | |
| 2024-06-18 | Magda Marquet | Director | Grant (A) | +70,000 opt | — | EDGAR | |
| 2024-06-18 | Philippe Calais | Director | Grant (A) | +70,000 opt | — | EDGAR | |
| 2024-06-18 | Thomas A Fitzgerald | Interim CEO, CFO | Grant (A) | +650,000 opt | — | EDGAR | |
| 2024-06-18 | Erik Manting | Director | Grant (A) | +70,000 opt | — | EDGAR | |
| 2023-10-02 | Thomas A Fitzgerald | Chief Financial Officer | Buy (P) | +49,350 | $0.51 | $25.2K | EDGAR |
| 2023-10-02 | Robert Michael Dudley | Chief Executive Officer | Buy (P) | +98,000 | $0.51 | $50.0K | EDGAR |
| 2023-06-22 | Robert Michael Dudley | Chief Executive Officer | Buy (P) | +18,607 | $2.62 | $48.7K | EDGAR |
| 2023-06-14 | Robert Michael Dudley | Chief Executive Officer | Buy (P) | +19,000 | $2.76 | $52.4K | EDGAR |
| 2023-06-13 | Robert Michael Dudley | Chief Executive Officer | Buy (P) | +19,000 | $2.76 | $52.4K | EDGAR |
| 2023-05-19 | Erik Manting | Director | Grant (A) | +45,000 opt | — | EDGAR | |
| 2023-05-19 | Thomas A Fitzgerald | Chief Financial Officer | Grant (A) | +300,000 opt | — | EDGAR | |
| 2023-05-19 | Robert Michael Dudley | Chief Executive Officer | Grant (A) | +735,000 opt | — | EDGAR | |
| 2023-05-19 | Magda Marquet | Director | Grant (A) | +45,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
RNAZ Insider Holdings
2 insiders · @ $1.71
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | CK Life Sciences Intl (Holdings) Inc | 10%+ Owner | 12,113,899 | $20.66M | $0 | 1 | 2026-08-05 |
| 2 | Thomas A Fitzgerald | Chief Financial Officer | 2 | $3 | $40.4K | 8 | 2026-09-11 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
RNAZ Board & Officers
As of SEC filings through Sep 21, 2026Directors 5
- Erik Manting · since Jul 8, 2021
- Magda Marquet · since Jul 8, 2021
- Philippe Calais · since Jul 8, 2021
- Elizabeth Czerepak · since Oct 6, 2025
- Jack E Stover · since Dec 19, 2025
Officers 1
- John A Tattory · Interim CFO · since Sep 10, 2026
10% owners 2
- CK Life Sciences Intl (Holdings) Inc (entity) · since Jul 27, 2026
- Defj, LLC (entity) · since Jul 27, 2026
Changes in the last 10 years (22)
| Sep 11, 2026 | Thomas A Fitzgerald reported in an SEC filing no longer being a director |
| Sep 11, 2026 | Thomas A Fitzgerald reported in an SEC filing no longer being Chief Financial Officer |
| Sep 10, 2026 | John A Tattory became Interim CFO |
| Jul 27, 2026 | Defj, LLC became a 10% owner |
| Jul 27, 2026 | CK Life Sciences Intl (Holdings) Inc became a 10% owner |
| Dec 19, 2025 | Jack E Stover became a director |
| Oct 6, 2025 | Elizabeth Czerepak became a director |
| Jan 10, 2024 | The company announced the departure of Robert Michael Dudley from the board in an SEC filing |
| Jan 10, 2024 | The company announced the departure of Robert Michael Dudley as Chief Executive Officer in an SEC filing |
| May 19, 2023 | Robert Michael Dudley no longer listed as a 10% owner in SEC filings |
| Dec 14, 2022 | Zdravka Medarova first listed as Chief Technology Officer in an SEC filing |
| Feb 3, 2022 | Thomas A Fitzgerald listed as Chief Financial Officer (previously VP, Chief Financial Officer) in SEC filings |
| Jul 8, 2021 | Zdravka Medarova became a 10% owner |
| Jul 8, 2021 | Thomas A Fitzgerald became a director |
| Jul 8, 2021 | Thomas A Fitzgerald became VP, Chief Financial Officer |
| Jul 8, 2021 | Robert Michael Dudley became a director |
| Jul 8, 2021 | Robert Michael Dudley became a 10% owner |
| Jul 8, 2021 | Robert Michael Dudley became Chief Executive Officer |
| Jul 8, 2021 | Philippe Calais became a director |
| Jul 8, 2021 | Magda Marquet became a director |
| Jul 8, 2021 | Erik Manting became a director |
| Jul 8, 2021 | Anna Moore became a 10% owner |
Not reported recently (2)
- Zdravka Medarova · Last reported as a 10% owner in an SEC filing dated Dec 14, 2022
- Anna Moore · Last reported as a 10% owner in an SEC filing dated Jul 8, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
1 ETF hold RNAZ
1 shown · $11.00K total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $10,996 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.